Cyclacel Current Deferred Revenue vs Short Term Investments Analysis

CYCC Stock

USD 0.40 0.01 2.56%

Cyclacel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cyclacel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclacel Pharmaceuticals is a good investment. Please check the relationship between Cyclacel Pharmaceuticals Current Deferred Revenue and its Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

Current Deferred Revenue vs Short Term Investments

Current Deferred Revenue vs Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclacel Pharmaceuticals Current Deferred Revenue account and Short Term Investments. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Cyclacel Pharmaceuticals' Current Deferred Revenue and Short Term Investments is 0.45. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of Cyclacel Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cyclacel Pharmaceuticals' Current Deferred Revenue and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Cyclacel Pharmaceuticals are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Current Deferred Revenue i.e., Cyclacel Pharmaceuticals' Current Deferred Revenue and Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.45

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Short Term Investments

Short Term Investments is an item under the current assets section of Cyclacel Pharmaceuticals balance sheet. It contains any investments Cyclacel Pharmaceuticals undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Cyclacel Pharmaceuticals can easily liquidate in the marketplace.

Most indicators from Cyclacel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to about 5.9 M.

	2023	2024 (projected)
Discontinued Operations	17.1K	30.4K
Cost Of Revenue	28.8K	27.4K

Discontinued Operations Cost Of Revenue

Cyclacel Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.57	0.23	0.15	-0.34	0.01	0.02	0.14	-0.06	0.0	0.18	0.13	-0.69	-0.32	0.83	0.09	-0.02	0.94	0.09	0.09	0.12	-0.08	0.0	0.93	0.11	0.09
Total Stockholder Equity	0.57		-0.53	-0.72	-0.03	0.72	-0.8	-0.69	0.21	-0.69	-0.52	-0.73	-0.98	0.02	0.92	-0.58	-0.37	0.79	0.27	-0.3	-0.73	-0.03	-0.63	0.82	-0.73	0.02
Retained Earnings	0.23	-0.53		0.83	-0.67	-0.93	0.8	0.91	-0.19	0.72	0.69	0.86	0.37	-0.4	-0.19	0.37	0.04	0.05	0.13	0.61	0.84	-0.47	0.6	-0.04	0.86	-0.24
Other Assets	0.15	-0.72	0.83		-0.24	-0.85	0.97	0.97	-0.41	0.77	0.82	0.99	0.6	-0.36	-0.41	0.78	0.38	-0.15	-0.27	0.43	1.0	-0.06	0.8	-0.21	0.99	0.02
Common Stock Shares Outstanding	-0.34	-0.03	-0.67	-0.24		0.45	-0.16	-0.42	-0.03	-0.19	-0.42	-0.29	0.14	0.47	-0.25	0.16	0.51	-0.36	-0.44	-0.37	-0.27	0.76	-0.23	-0.28	-0.28	0.29
Other Stockholder Equity	0.01	0.72	-0.93	-0.85	0.45		-0.88	-0.9	0.21	-0.76	-0.68	-0.87	-0.59	0.35	0.44	-0.47	-0.17	0.21	-0.02	-0.58	-0.86	0.31	-0.68	0.3	-0.88	0.22
Total Liab	0.02	-0.8	0.8	0.97	-0.16	-0.88		0.93	-0.3	0.84	0.75	0.97	0.69	-0.26	-0.53	0.79	0.46	-0.28	-0.28	0.42	0.97	0.02	0.78	-0.33	0.97	0.04
Short Long Term Debt Total	0.14	-0.69	0.91	0.97	-0.42	-0.9	0.93		-0.45	0.72	0.85	0.99	0.57	-0.43	-0.38	0.62	0.16	-0.12	-0.16	0.47	0.98	-0.31	0.8	-0.2	0.99	-0.15
Other Current Liab	-0.06	0.21	-0.19	-0.41	-0.03	0.21	-0.3	-0.45		0.22	-0.57	-0.44	-0.24	0.57	0.14	-0.29	0.25	0.02	0.27	-0.04	-0.43	0.28	-0.56	0.09	-0.44	0.22
Total Current Liabilities	0.0	-0.69	0.72	0.77	-0.19	-0.76	0.84	0.72	0.22		0.41	0.75	0.56	0.17	-0.44	0.57	0.58	-0.26	-0.13	0.39	0.76	0.1	0.43	-0.27	0.76	0.09
Property Plant And Equipment Net	0.18	-0.52	0.69	0.82	-0.42	-0.68	0.75	0.85	-0.57	0.41		0.84	0.46	-0.69	-0.27	0.69	-0.09	-0.05	-0.21	0.32	0.84	-0.26	0.96	-0.13	0.83	-0.11
Current Deferred Revenue	0.13	-0.73	0.86	0.99	-0.29	-0.87	0.97	0.99	-0.44	0.75	0.84		0.61	-0.38	-0.42	0.73	0.29	-0.16	-0.24	0.45	1.0	-0.16	0.81	-0.23	1.0	-0.07
Net Debt	-0.69	-0.98	0.37	0.6	0.14	-0.59	0.69	0.57	-0.24	0.56	0.46	0.61		0.02	-0.97	0.54	0.32	-0.88	-0.31	0.18	0.62	0.07	0.6	-0.91	0.62	-0.01
Accounts Payable	-0.32	0.02	-0.4	-0.36	0.47	0.35	-0.26	-0.43	0.57	0.17	-0.69	-0.38	0.02		-0.15	-0.28	0.42	-0.27	-0.05	-0.28	-0.38	0.38	-0.61	-0.18	-0.37	0.17
Cash	0.83	0.92	-0.19	-0.41	-0.25	0.44	-0.53	-0.38	0.14	-0.44	-0.27	-0.42	-0.97	-0.15		-0.41	-0.3	0.96	0.28	-0.09	-0.43	-0.13	-0.44	0.97	-0.43	-0.01
Non Current Assets Total	0.09	-0.58	0.37	0.78	0.16	-0.47	0.79	0.62	-0.29	0.57	0.69	0.73	0.54	-0.28	-0.41		0.61	-0.23	-0.47	0.19	0.76	0.48	0.74	-0.23	0.72	0.43
Non Currrent Assets Other	-0.02	-0.37	0.04	0.38	0.51	-0.17	0.46	0.16	0.25	0.58	-0.09	0.29	0.32	0.42	-0.3	0.61		-0.24	-0.28	0.13	0.33	0.79	-0.01	-0.17	0.3	0.6
Cash And Short Term Investments	0.94	0.79	0.05	-0.15	-0.36	0.21	-0.28	-0.12	0.02	-0.26	-0.05	-0.16	-0.88	-0.27	0.96	-0.23	-0.24		0.23	0.04	-0.17	-0.19	-0.24	0.99	-0.17	-0.03
Common Stock Total Equity	0.09	0.27	0.13	-0.27	-0.44	-0.02	-0.28	-0.16	0.27	-0.13	-0.21	-0.24	-0.31	-0.05	0.28	-0.47	-0.28	0.23		0.58	-0.25	-0.32	-0.29	0.21	-0.24	-0.15
Short Term Investments	0.09	-0.3	0.61	0.43	-0.37	-0.58	0.42	0.47	-0.04	0.39	0.32	0.45	0.18	-0.28	-0.09	0.19	0.13	0.04	0.58		0.44	-0.12	0.29	-0.05	0.45	-0.1
Non Current Liabilities Total	0.12	-0.73	0.84	1.0	-0.27	-0.86	0.97	0.98	-0.43	0.76	0.84	1.0	0.62	-0.38	-0.43	0.76	0.33	-0.17	-0.25	0.44		-0.11	0.82	-0.24	1.0	-0.01
Other Current Assets	-0.08	-0.03	-0.47	-0.06	0.76	0.31	0.02	-0.31	0.28	0.1	-0.26	-0.16	0.07	0.38	-0.13	0.48	0.79	-0.19	-0.32	-0.12	-0.11		-0.12	-0.1	-0.15	0.61
Property Plant And Equipment Gross	0.0	-0.63	0.6	0.8	-0.23	-0.68	0.78	0.8	-0.56	0.43	0.96	0.81	0.6	-0.61	-0.44	0.74	-0.01	-0.24	-0.29	0.29	0.82	-0.12		-0.31	0.81	-0.14
Total Current Assets	0.93	0.82	-0.04	-0.21	-0.28	0.3	-0.33	-0.2	0.09	-0.27	-0.13	-0.23	-0.91	-0.18	0.97	-0.23	-0.17	0.99	0.21	-0.05	-0.24	-0.1	-0.31		-0.24	0.05
Short Term Debt	0.11	-0.73	0.86	0.99	-0.28	-0.88	0.97	0.99	-0.44	0.76	0.83	1.0	0.62	-0.37	-0.43	0.72	0.3	-0.17	-0.24	0.45	1.0	-0.15	0.81	-0.24		-0.08
Common Stock	0.09	0.02	-0.24	0.02	0.29	0.22	0.04	-0.15	0.22	0.09	-0.11	-0.07	-0.01	0.17	-0.01	0.43	0.6	-0.03	-0.15	-0.1	-0.01	0.61	-0.14	0.05	-0.08

Click cells to compare fundamentals

Cyclacel Pharmaceuticals Account Relationship Matchups

Cyclacel Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.3M	36.8M	42.6M	27.5M	8.8M	8.4M
Total Stockholder Equity	11.7M	33.3M	37.3M	15.5M	607K	576.7K
Retained Earnings	(357.6M)	(366.1M)	(385.0M)	(406.2M)	(428.3M)	(406.9M)
Common Stock Shares Outstanding	54.4K	242.2K	595.1K	657.6K	850.8K	893.4K
Liabilities And Stockholders Equity	15.3M	36.8M	42.6M	27.5M	8.8M	8.4M
Other Stockholder Equity	370.1M	400.1M	423.0M	414.0M	429.8M	284.3M
Total Liab	3.6M	3.5M	5.3M	12.0M	8.2M	14.1M
Other Current Liab	1.5M	2.0M	3.2M	4.8M	4.6M	3.4M
Total Current Liabilities	2.4M	2.5M	5.3M	7.4M	8.2M	5.8M
Property Plant And Equipment Net	1.3M	1.3M	94K	174K	102K	96.9K
Net Debt	(10.7M)	(32.3M)	(36.5M)	(18.2M)	(3.3M)	(3.5M)
Accounts Payable	890K	514K	2.1M	2.6M	3.5M	2.2M
Cash	11.9M	33.4M	36.6M	18.3M	3.4M	3.2M
Non Current Assets Total	1.3M	1.3M	1.6M	3.1M	1.4M	1.7M
Non Currrent Assets Other	(1.3M)	(1.3M)	1.6M	2.9M	1.3M	1.3M
Cash And Short Term Investments	11.9M	33.4M	36.6M	18.3M	3.4M	3.2M
Non Current Liabilities Total	1.2M	1.1M	30K	4.6M	37K	35.2K
Other Current Assets	103K	750K	4.4M	6.1M	4.1M	4.3M
Property Plant And Equipment Gross	1.3M	1.3M	94K	174K	522K	839.0K
Total Current Assets	14.0M	35.5M	40.9M	24.4M	7.4M	7.1M
Accumulated Other Comprehensive Income	(819K)	(746K)	(748K)	(1.3M)	(908K)	(953.4K)
Common Stock	17K	6K	10K	4.5M	1K	950.0
Net Receivables	1.3M	1.3M	3.7M	5.6M	2.9M	2.7M
Inventory	703K	684K	577K	(5.6M)	(5.1M)	(4.8M)
Property Plant Equipment	27K	106K	94K	174K	156.6K	148.8K
Retained Earnings Total Equity	(342.5M)	(349.8M)	(357.6M)	(366.1M)	(329.5M)	(345.9M)
Net Tangible Assets	11.7M	33.3M	37.3M	15.5M	17.8M	23.9M
Capital Surpluse	365.1M	365.8M	370.1M	400.1M	460.1M	394.6M
Non Current Liabilities Other	124K	100K	1.2M	1.1M	1.2M	1.3M
Net Invested Capital	11.7M	33.3M	37.3M	20.0M	607K	576.7K
Net Working Capital	11.6M	33.0M	35.6M	17.0M	(717K)	(681.2K)
Capital Stock	17K	6K	10K	4.5M	1K	950.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:

How To Invest In Cyclacel

Details

Is Cyclacel Stock a good investment?

Details

What is Cyclacel Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(27.40)

Revenue Per Share

0.044

Quarterly Revenue Growth

(0.99)

Return On Assets

(1.03)

Return On Equity

(5.71)

The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclacel Current Deferred Revenue vs Short Term Investments Analysis

Current Deferred Revenue vs Short Term Investments

Current Deferred Revenue vs Short Term Investments Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Short Term Investments

Cyclacel Pharmaceuticals fundamental ratios Correlations

Cyclacel Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclacel Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Other Assets
Non Current Liabilities Total	+ 1.0	Current Deferred Revenue
Short Term Debt	+ 1.0	Current Deferred Revenue
Short Term Debt	+ 1.0	Non Current Liabilities Total
Current Deferred Revenue	+ 0.99	Other Assets
Short Term Debt	+ 0.99	Other Assets

Net Debt	- 0.98	Total Stockholder Equity
Cash	- 0.97	Net Debt
Other Stockholder Equity	- 0.93	Retained Earnings
Total Current Assets	- 0.91	Net Debt
Short Long Term Debt Total	- 0.9	Other Stockholder Equity
Cash And Short Term Investments	- 0.88	Net Debt